GSK PLC-SPON ADR (GSK) Stock News

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?

Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025.

GSK Enters Agreement to Acquire IDRx, Inc.

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

August 2025 Options Now Available For GSK

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS.

AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?

AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025.

Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse

Glaxo (GSK) Down 6.6% Since Last Earnings Report: Can It Rebound?

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.